Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Pabinger

Showing results (271-280 of 367) with videos related to

Pageof 37
Sort By:
Thrombosis Research|January 24, 2015
An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversalÁron Altorjay, Éva Szabó, Zoltán Boda, et al.
Research and Practice in Thrombosis and Haemostasis|August 1, 2022
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studiesPratima Chowdary, Margareta Holmström, Johnny N Mahlangu, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2025
Walking capacity and venous claudication after deep vein thrombosis: prospective follow-up, risk factors, and quality of lifeDaniel Steiner, Stephan Nopp, Timothy Hoberstorfer, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED studyNikola Vladic, Cornelia Englisch, Julia Maria Berger, et al.
Blood Advances|November 30, 2021
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donorsHelmut Schweiger, Judit Rejtő, Christoph J Hofbauer, et al.
The New England Journal of Medicine|November 12, 2010
Romiplostim or standard of care in patients with immune thrombocytopeniaDavid J Kuter, Mathias Rummel, Ralph Boccia, et al.
Wiener Klinische Wochenschrift|June 26, 2013
[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts]Herbert Watzke, Helfried Metzler, Ansgar Weltermann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 10, 2025
Efficacy and Safety of rVIII-SingleChain in Surgical ProphylaxisFaraizah Abdul Karim, Johnny Mahlangu, Claudia Djambas Khayat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2023
An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand diseaseWolfgang Miesbach, Susan Halimeh, Helen Platokouki, et al.
Thrombosis Research|August 19, 2025
Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular eventsRafaela Vostatek, Taras Afonyushkin, Maria Ozsvar Kozma, et al.
Pageof 37

Showing results (271-280 of 367) with videos related to

Sort By:
Pageof 37
Thrombosis Research|January 24, 2015
An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversalÁron Altorjay, Éva Szabó, Zoltán Boda, et al.
Research and Practice in Thrombosis and Haemostasis|August 1, 2022
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studiesPratima Chowdary, Margareta Holmström, Johnny N Mahlangu, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2025
Walking capacity and venous claudication after deep vein thrombosis: prospective follow-up, risk factors, and quality of lifeDaniel Steiner, Stephan Nopp, Timothy Hoberstorfer, et al.
Research and Practice in Thrombosis and Haemostasis|July 21, 2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED studyNikola Vladic, Cornelia Englisch, Julia Maria Berger, et al.
Blood Advances|November 30, 2021
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donorsHelmut Schweiger, Judit Rejtő, Christoph J Hofbauer, et al.
The New England Journal of Medicine|November 12, 2010
Romiplostim or standard of care in patients with immune thrombocytopeniaDavid J Kuter, Mathias Rummel, Ralph Boccia, et al.
Wiener Klinische Wochenschrift|June 26, 2013
[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts]Herbert Watzke, Helfried Metzler, Ansgar Weltermann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 10, 2025
Efficacy and Safety of rVIII-SingleChain in Surgical ProphylaxisFaraizah Abdul Karim, Johnny Mahlangu, Claudia Djambas Khayat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2023
An open-label, multi-centre, post-marketing study to assess the efficacy and safety of a plasma-derived VWF/FVIII concentrate in patients with von Willebrand diseaseWolfgang Miesbach, Susan Halimeh, Helen Platokouki, et al.
Thrombosis Research|August 19, 2025
Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular eventsRafaela Vostatek, Taras Afonyushkin, Maria Ozsvar Kozma, et al.
Pageof 37